BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ:BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on January 4, 2024, it received a Foreign Delinquency Compliance Plan Alert Letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). In the Letter, the staff of Nasdaq notified the Company that it is not in compliance with Nasdaq Listing Rule 5250(c)(2), because it has not timely filed its Form 6-K for the period ended June 30, 2023 (the “Filing”).
Related news for (BYSI)
- BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment
- BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update
- BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones
- BeyondSpring Files 2024 Annual Report on Form 10-K
- BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies